GHRS vs. ORIC, NUVB, CVAC, VERV, ZYME, MLYS, OLMA, LYEL, WVE, and SIGA
Should you be buying GH Research stock or one of its competitors? The main competitors of GH Research include ORIC Pharmaceuticals (ORIC), Nuvation Bio (NUVB), CureVac (CVAC), Verve Therapeutics (VERV), Zymeworks (ZYME), Mineralys Therapeutics (MLYS), Olema Pharmaceuticals (OLMA), Lyell Immunopharma (LYEL), Wave Life Sciences (WVE), and SIGA Technologies (SIGA). These companies are all part of the "pharmaceutical preparations" industry.
GH Research (NASDAQ:GHRS) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking.
GH Research is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, GH Research had 2 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 4 mentions for GH Research and 2 mentions for ORIC Pharmaceuticals. ORIC Pharmaceuticals' average media sentiment score of 0.53 beat GH Research's score of 0.43 indicating that ORIC Pharmaceuticals is being referred to more favorably in the news media.
56.9% of GH Research shares are held by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 5.3% of ORIC Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
GH Research presently has a consensus price target of $39.50, indicating a potential upside of 238.18%. ORIC Pharmaceuticals has a consensus price target of $19.80, indicating a potential upside of 103.91%. Given GH Research's higher probable upside, research analysts plainly believe GH Research is more favorable than ORIC Pharmaceuticals.
ORIC Pharmaceuticals received 28 more outperform votes than GH Research when rated by MarketBeat users. However, 65.38% of users gave GH Research an outperform vote while only 65.22% of users gave ORIC Pharmaceuticals an outperform vote.
GH Research has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
GH Research's return on equity of -15.48% beat ORIC Pharmaceuticals' return on equity.
Summary
GH Research beats ORIC Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get GH Research News Delivered to You Automatically
Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GH Research Competitors List
Related Companies and Tools
